期刊
NATURE REVIEWS DRUG DISCOVERY
卷 14, 期 9, 页码 623-641出版社
NATURE PORTFOLIO
DOI: 10.1038/nrd4623
关键词
-
资金
- Torsten Soderbergs Foundation
- Jochnick Foundation
- Swedish Research Council
- Swedish Heart and Lung Foundation
- US National Institutes of Health (NIH) [2R01HL098032, 1R01HL125886-01, P01HL103455, T32 HL110849, T32 HL007563]
- Institute for Transfusion Medicine
- Hemophilia Center of Western Pennsylvania
- Stockholm County Council (ALF)
Nitric oxide (NO) is a key signalling molecule in the cardiovascular, immune and central nervous systems, and crucial steps in the regulation of NO bioavailability in health and disease are well characterized. Although early approaches to therapeutically modulate NO bioavailability failed in clinical trials, an enhanced understanding of fundamental subcellular signalling has enabled a range of novel therapeutic approaches to be identified. These include the identification of: new pathways for enhancing NO synthase activity; ways to amplify the nitrate-nitrite-NO pathway; novel classes of NO-donating drugs; drugs that limit NO metabolism through effects on reactive oxygen species; and ways to modulate downstream phosphodiesterases and soluble guanylyl cyclases. In this Review, we discuss these latest developments, with a focus on cardiovascular disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据